CDI-988 — Initial data
Sep 2026–Apr 2027
We look forward to reporting preliminary results near the end of 2026 or early 2027 and to advancing CDI-988 as a potential first-in-class oral antiviral for norovirus.Source filing
catalyst calendar
COCRYSTAL PHARMA INC · Data as of 2026-10-25
Sep 2026–Apr 2027
We look forward to reporting preliminary results near the end of 2026 or early 2027 and to advancing CDI-988 as a potential first-in-class oral antiviral for norovirus.Source filing